Investing.com - Cellebrite (NASDAQ: CLBT) reported third quarter EPS of $0.140, $0.07 better than the analyst estimate of $0.070. Revenue for the quarter came in at $106.86M versus the consensus estimate of $102.07M.
Guidance
Cellebrite sees Q4 2024 revenue of $105.000M-$109.000M versus the analyst consensus of $107.000M.
Cellebrite's stock price closed at $19.15. It is up 41.330% in the last 3 months and up 164.140% in the last 12 months.
Cellebrite saw 7 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Cellebrite's stock price’s past reactions to earnings here.
According to InvestingPro, Cellebrite's Financial Health score is "great performance".
Check out Cellebrite's recent earnings performance, and Cellebrite's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar